Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review

We report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase-positive large B-cell lymphoma. A pathological examination showed plasma-cell immunophenotype negative for mature B-lymphocyte markers. The patient received three cycles of an “alectinib + Vincristine +...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hongxia Wang, Junjun Bai, Bei Zhang, Zhixin Pei, Yingxin Zhao, Jingjing Gu, Zhiyu Fang, Miaomiao Liu, Xun Liang, Qinglin Song
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	ALK+ LBCL alectinib bortezomib lenalidomide BV monoclonal antibody
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1480880/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
by: Kaili Huang, et al.
Published: (2025-04-01)

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01)

Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report
by: Kei Kunimasa, et al.
Published: (2024-12-01)

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib
by: Feng Jin, et al.
Published: (2025-06-01)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
by: Luca Mastrantoni, et al.
Published: (2024-01-01)

CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01)

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01)

Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib
by: Yinyin Xue, et al.
Published: (2025-08-01)

Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib
by: Vito Longo, et al.
Published: (2024-11-01)

Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India
by: Ajaykumar Singh, et al.

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01)

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report
by: Yun Li, et al.
Published: (2025-05-01)

Alectinib-Induced Hemolysis in a Case of ALK-Positive Metastatic Lung Adenocarcinoma: A Case Report with Review of Literature
by: Suparna Ajit Rao, et al.

Case Report: Ocular metastasis from ALK-rearranged pulmonary adenocarcinoma presenting as a pseudo-syndrome of anterior uveitis
by: Cong Zhao, et al.
Published: (2025-08-01)

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
by: Ceva Wicaksono Pitoyo, et al.
Published: (2022-07-01)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
by: Hiroshi Hashimoto, et al.
Published: (2022-04-01)

Modern treatment of ALK-positive non-small cell lung cancer
by: D. A. Kharagezov, et al.
Published: (2022-06-01)

Safety of brigatinib following alectinib-induced-pneumonitis: Case report
by: Blerina Resuli, et al.
Published: (2025-01-01)

Recent advances in the diagnosis and treatment of membranoproliferative glomerulonephritis with monoclonal immunoglobulin deposition
by: Zhang Yuan-yuan, et al.
Published: (2022-03-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023-11-01)

Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
by: Qiran Wei, et al.
Published: (2024-11-01)

Revaccination following CAR-T therapy: a needs assessment
by: Robert Clayden, et al.
Published: (2025-12-01)

Chemometrically assisted optimization and validation of the HPLC method for the analysis of alectinib and its related impurity with measurement uncertainty evaluation and whiteness, blueness, and greenness profile assessments
by: Serkan Levent, et al.
Published: (2025-05-01)

Alectinib-Loaded Chitosan–Alginate Nanoparticles: A Novel Synthesis Method with In Vitro and In Vivo Evaluations
by: Tha’er Ata, et al.
Published: (2025-04-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Magnesium Isoglycyrrhizinate Alleviates Alectinib-Induced Hepatotoxicity by Inhibiting Mitochondrial Damage-Mediated Pyroptosis
by: Chen Y, et al.
Published: (2025-07-01)

A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01)

On Anisotropic $BV$-Spaces
by: P. Kogut
Published: (2025-08-01)

Lung Adenocarcinoma Expressing an EML4‐ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report
by: Mami Ozaki, et al.
Published: (2025-08-01)

Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib
by: Tamara vanDonge, et al.
Published: (2025-06-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
by: SV Semochkin, et al.
Published: (2018-12-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
by: Dafeng Guo, et al.
Published: (2022-12-01)